CN104288164B - 一种用于预防急性酒精性肝损伤的药物组合物 - Google Patents
一种用于预防急性酒精性肝损伤的药物组合物 Download PDFInfo
- Publication number
- CN104288164B CN104288164B CN201410491590.2A CN201410491590A CN104288164B CN 104288164 B CN104288164 B CN 104288164B CN 201410491590 A CN201410491590 A CN 201410491590A CN 104288164 B CN104288164 B CN 104288164B
- Authority
- CN
- China
- Prior art keywords
- glucosamine
- curcumin
- pharmaceutical composition
- group
- alcoholic liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 231100000753 hepatic injury Toxicity 0.000 title claims abstract description 34
- 230000001154 acute effect Effects 0.000 title claims abstract description 25
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 22
- 230000001476 alcoholic effect Effects 0.000 title abstract description 18
- 206010067125 Liver injury Diseases 0.000 title abstract description 17
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 109
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims abstract description 74
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 71
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims abstract description 71
- 229960002442 glucosamine Drugs 0.000 claims abstract description 71
- 229940109262 curcumin Drugs 0.000 claims abstract description 51
- 239000004148 curcumin Substances 0.000 claims abstract description 51
- 235000012754 curcumin Nutrition 0.000 claims abstract description 51
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims abstract description 51
- 239000003814 drug Substances 0.000 claims abstract description 20
- 239000002552 dosage form Substances 0.000 claims abstract description 13
- 229940079593 drug Drugs 0.000 claims abstract description 9
- 239000000463 material Substances 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 25
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 claims description 16
- 229960001911 glucosamine hydrochloride Drugs 0.000 claims description 16
- 229920002472 Starch Polymers 0.000 claims description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 15
- 239000008107 starch Substances 0.000 claims description 15
- 235000019698 starch Nutrition 0.000 claims description 15
- 239000008187 granular material Substances 0.000 claims description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- -1 hydroxyl isomaltulose Chemical compound 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 239000004615 ingredient Substances 0.000 claims description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 10
- 239000003826 tablet Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 7
- 239000000741 silica gel Substances 0.000 claims description 7
- 229910002027 silica gel Inorganic materials 0.000 claims description 7
- 239000002002 slurry Substances 0.000 claims description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- 229920001353 Dextrin Polymers 0.000 claims description 5
- 239000004375 Dextrin Substances 0.000 claims description 5
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 238000010612 desalination reaction Methods 0.000 claims description 5
- 235000019425 dextrin Nutrition 0.000 claims description 5
- 239000006196 drop Substances 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 5
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- 230000009967 tasteless effect Effects 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 239000000811 xylitol Substances 0.000 claims description 5
- 229960002675 xylitol Drugs 0.000 claims description 5
- 235000010447 xylitol Nutrition 0.000 claims description 5
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 5
- 229920000881 Modified starch Polymers 0.000 claims description 4
- 235000021355 Stearic acid Nutrition 0.000 claims description 4
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 4
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 claims description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 4
- 239000008117 stearic acid Substances 0.000 claims description 4
- 235000019441 ethanol Nutrition 0.000 claims description 3
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 claims description 3
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 3
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims 1
- 235000015424 sodium Nutrition 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 abstract description 5
- 239000000047 product Substances 0.000 abstract description 5
- 230000002195 synergetic effect Effects 0.000 abstract description 5
- 230000036541 health Effects 0.000 abstract description 4
- 150000003254 radicals Chemical class 0.000 abstract description 4
- 239000003963 antioxidant agent Substances 0.000 abstract description 3
- 235000015872 dietary supplement Nutrition 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 238000002474 experimental method Methods 0.000 abstract description 3
- 241001465754 Metazoa Species 0.000 abstract description 2
- 238000005516 engineering process Methods 0.000 abstract description 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 22
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 210000004185 liver Anatomy 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 13
- 235000003392 Curcuma domestica Nutrition 0.000 description 12
- 244000008991 Curcuma longa Species 0.000 description 12
- 235000003373 curcuma longa Nutrition 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 235000013976 turmeric Nutrition 0.000 description 12
- 230000003203 everyday effect Effects 0.000 description 9
- 230000002440 hepatic effect Effects 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 210000001508 eye Anatomy 0.000 description 7
- 210000005228 liver tissue Anatomy 0.000 description 7
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 239000000725 suspension Substances 0.000 description 5
- JCZPMGDSEAFWDY-SQOUGZDYSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanamide Chemical group NC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO JCZPMGDSEAFWDY-SQOUGZDYSA-N 0.000 description 4
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- 239000005913 Maltodextrin Substances 0.000 description 4
- 229920002774 Maltodextrin Polymers 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 229940035034 maltodextrin Drugs 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000007779 soft material Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 229920002101 Chitin Polymers 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 240000006394 Sorghum bicolor Species 0.000 description 2
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000037308 hair color Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 102000001284 I-kappa-B kinase Human genes 0.000 description 1
- 108060006678 I-kappa-B kinase Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001582888 Lobus Species 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000594182 Sarcophaga sigma Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000009940 knitting Methods 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000013435 necrotic lesion Diseases 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及一种用于预防急性酒精性肝损伤的药物组合物,涉及医药技术领域,该药物组合物由主料和辅料经药物制剂技术加工制成常规剂型,主料由氨基葡萄糖和姜黄素组成,氨基葡萄糖与姜黄素的重量比为3~6:1。本发明利用氨基葡萄糖和姜黄素的清除自由基和抗氧化作用,利用氨基葡萄糖和姜黄素作为抗氧化剂,经动物实验证明两者具有协同增效保护酒精所致的酒精性肝损伤的作用,为临床提供了一种能够有效预防急性酒精性肝损伤的药物组合物,可用于制备预防急性酒精性肝损伤相关病症的药品、保健品以及膳食补充剂。
Description
技术领域
本发明涉及一种药物组合物,具体是一种用于预防急性酒精性肝损伤的药物组合物,可应用于预防急性酒精性肝损伤病症。
背景技术
酒精性肝病(alcoholic liver disease,ALD)是由于长期大量饮酒而导致的肝脏损伤,是临床上一种极常见的肝脏疾患。根据病情和病程,酒精性肝病可分为酒精性脂肪肝、酒精性肝炎、酒精性肝纤维化、酒精性肝硬化4个阶段,并常有重叠的现象存在。我国有悠久的饮酒文化,短时间内难以戒除,且随着生活条件提高,国民中酗酒时常发生,临床所见酒精性肝病也有逐年增多的趋势,因此,探索早期预防措施应该是目前酒精性肝损伤治疗的可行出路。
发明内容
本发明所要解决的技术问题是提供一种用于预防急性酒精性肝损伤的药物组合物。
本发明解决上述技术问题所采用的技术方案为:一种用于预防急性酒精性肝损伤的药物组合物,由主料和辅料经药物制剂技术加工制成常规剂型,所述的主料由氨基葡萄糖和姜黄素组成,所述的氨基葡萄糖与所述的姜黄素的重量比为3~6:1。
酒精性肝病的发病机制是多因素的,目前研究较多的主要集中在酒精及其代谢产物乙醛的直接肝毒性、氧化应激与活性氧自由基损伤、细胞因子与内毒素介导的免疫炎症机制等。其中酒精及其代谢过程中产生的大量活性氧簇(reactive oxygen species,ROS)引起的氧化应激被认为是酒精性肝病最重要的早期发病机理。氨基葡萄糖是由甲壳素经降解与脱乙酰化得到,而甲壳素是自然界中生物合成的第二大可再生资源;姜黄素是从姜科、天南星科中的一些植物的根茎中提取的一种化学成分,其原料来源也十分广泛,因此,本发明药物组合物具有原料来源天然和广泛的特点。
经药理学实验发现,氨基葡萄糖分子上的氨基可以与酒精的代谢产物乙醛发生反应,减弱乙醛对人体细胞的危害,减少急性酒精性肝损伤,达到保护肝脏的目的,但单独使用氨基葡萄糖作为主料时,所需药物的剂量较大。姜黄是我国临床最常用的一味中药,姜黄素是其主要成分,姜黄素除了能提高酒精诱导的处于氧化应激的肝脏中各氧化酶的活性外,还能抑制一氧化氮合酶的形成,通过抑制IκB激酶的活性而抑制核炎症因子(NF-κB)的活化,进而抑制肝脏的炎症,对肝脏起到保护作用,但是姜黄素的肝脏首过作用大,且有一定的刺激性。在价格方面,姜黄素是氨基葡萄糖的8~12倍。因此使用氨基葡萄糖或姜黄素作为药物的主料单独用药,均存在一定的缺陷和不足。
本发明以氨基葡萄糖为主,采用姜黄素辅助氨基葡萄糖,利用氨基葡萄糖和姜黄素能捕捉脂质过氧化链式反应中产生的自由基、抑制脂质过氧化、并在某种程度上提高内源性抗氧化物酶的活性的特点,采用氨基葡萄糖和姜黄素作为抗氧化剂,通过两者的协同增效作用干预保护酒精所致的酒精性肝损伤,不仅可以降低氨基葡萄糖的剂量,还可以提高姜黄素的口服利用率,同时对酒精性肝损伤的预防效果优于同剂量的两者单独用药,获得了较好的护肝效果,为酒精性肝损伤的防治提供新依据,同时还具有成本低、刺激小等优点。
所述的剂型为口服液、颗粒剂、胶囊剂、片剂和滴丸剂中的任一种。本发明组合物中的主料配以药学上可接受的各种药用辅料,可制成各种普通制剂,如口服液、颗粒剂、胶囊剂、片剂、速崩片、滴丸剂等,也可制成缓释制剂,如缓释片、缓释胶囊剂等。
所述的辅料为淀粉、麦芽糊精、糊精、蔗糖、木糖醇、异麦芽糖醇、麦芽糖醇、甘露醇、微晶纤维素、聚乙二醇-6000、预胶化淀粉、羧甲基纤维素钠、羧甲基淀粉钠、聚乙烯吡咯烷酮、交联聚维酮、微粉硅胶、硬脂酸、硬脂酸镁、水、甘油、淀粉浆、乙醇、尼泊金酯和香精中的一种或几种。辅料指的是药学上可接受的药用辅料,该辅料为药学领域常规的药物载体和附加剂,上述各个辅料的作用不尽相同:溶剂如水;填充剂如淀粉、麦芽糊精、糊精、蔗糖、木糖醇、异麦芽糖醇、麦芽糖醇、甘露醇、微晶纤维素、聚乙二醇-6000等;润湿剂与粘合剂如水、乙醇、淀粉浆、羧甲基纤维素钠、聚乙烯吡咯烷酮等;崩解剂如干淀粉、预胶化淀粉、羧甲基淀粉钠、交联聚维酮等;润滑剂如微粉硅胶、硬脂酸镁等;矫味剂如香精、甜味剂等。
上述药物组合物的制备方法包括以下步骤:
1)准备氨基葡萄糖盐酸盐、姜黄素、辅料适量;
2)氨基葡萄糖的预处理:将氨基葡萄糖盐酸盐粉碎后过80~300目筛网,然后将过筛得到的氨基葡萄糖盐酸盐与三乙胺按0.6~1.2:1摩尔比混合得到混合物,再加入该混合物重量100~500%的95%的乙醇水溶液,于室温条件下搅拌3~8h脱盐酸,重复三次,抽滤得到固形物,对该固形物用95%乙醇洗涤3~5次至无味,得到氨基葡萄糖,将氨基葡萄糖置于真空干燥器中干燥,备用;
3)将得到的氨基葡萄糖以及预先准备的姜黄素和辅料按药物制剂技术加工制成所需剂型,该剂型的药物组合物的主料由氨基葡萄糖和姜黄素组成,氨基葡萄糖与姜黄素的重量比为3~6:1。
上述药物组合物在制备预防急性酒精性肝损伤相关病症的药品、保健品以及膳食补充剂中的应用。本发明的药物组合物可用于制备预防急性酒精性肝损伤相关病症的药品、保健品以及膳食补充剂。
与现有技术相比,本发明的优点在于:本发明公开的药物组合物的主料由氨基葡萄糖和姜黄素组成,氨基葡萄糖与姜黄素的重量比为3~6:1。本发明利用氨基葡萄糖和姜黄素具有清除自由基和抗氧化的作用,利用氨基葡萄糖和姜黄素作为抗氧化剂,经动物实验证明两者具有协同增效保护酒精所致的酒精性肝损伤的作用,为临床提供了一种能够有效预防急性酒精性肝损伤的药物组合物,可用于制备防治酒精性肝损伤的相关病症的药品、保健品以及膳食补充剂。
附图说明
图1为造模2周后正常组小鼠肝脏组织切片结果;
图2为造模2周后对照组小鼠肝脏组织切片结果;
图3为造模2周后氨基葡糖组小鼠肝脏组织切片结果;
图4为造模2周后姜黄素组小鼠肝脏组织切片结果;
图5为造模2周后给药组1小鼠肝脏组织切片结果;
图6为造模2周后给药组2小鼠肝脏组织切片结果。
具体实施方式
以下结合附图实施例对本发明作进一步详细描述。
首先通过动物实验对氨基葡萄糖和姜黄素的协同增效保护酒精性肝损伤的作用进行实验验证:
选取购自浙江医学科学院实验动物中心的清洁级ICR小鼠,18~22g,雄性,48只,许可证号Scxk(浙)2008-0033。将48只雄性小白鼠随机分为6组:正常组、对照组、氨基葡萄糖组、姜黄素组、给药组1、给药组2。对于这6组小白鼠,每天给予正常饲料和饮水,除正常组外,其余组用56°红星二锅头按每天0.14mL/10g的剂量联系灌胃2周,利用小鼠模拟建立急性酒精性肝损伤模型。其中,对照组未使用任何预防肝损伤的药物,仅按每天0.14mL/10g的剂量给以生理盐水;氨基葡萄糖组按每天0.1mL/10g的剂量给70mg/mL的氨基葡萄糖溶液;姜黄素组按每天0.1mL/10g的剂量给30mg/mL姜黄素混悬液(用1%的羧甲基纤维素钠溶液配制而成);给药组1按每天0.1mL/10g的剂量给由25mg/mL的氨基葡萄糖溶液和5mg/mL姜黄素混悬液组成的药物混合物;给药组2按每天0.1mL/10g的剂量给由55mg/mL的氨基葡萄糖溶液和15mg/mL姜黄素混悬液组成的药物混合物。
每天观察各组小鼠的健康状况、摄食、饮水是否有异常,每天定时灌胃,并根据体重调整灌胃剂量。造模后进行以下各项观察和检测。
1、一般状态观察
造模2周过程中发现:正常组小鼠食欲旺盛,毛色光亮,两周后体重明显上升。对照组小鼠灌酒后20min内多数呈现正反射失调,心跳明显加快,醉酒时间延长,但是后期小鼠对酒精的抗性有所增加,正反射失调只数减少,2周后小鼠毛色呈粗糙状态,体重增加不大,且有2只在喂养过程中死亡。各药物组小鼠也有正反射失调现象,但是醉酒时间缩短,饮食比对照组活跃,2周后小鼠体重上升明显,没有死亡情况。
2、血清与肝组织生化指标检测
各组小鼠造模2周后,夜间禁食12h,眼球取血,血液在室温放置30min。待血液凝固后,于4℃、3000r·min-1离心15min,取上清液,按照试剂盒提供的方法检测血清ALT,AST。
称取小鼠肝脏2g,剪碎,用生理盐水20mL制成10%的肝匀浆液,于3000~4000r·min-1离心10min,取上清液备用,按照试剂盒提供方法检测肝组织SOD,MDA。
对上述ALT、AST、SOD、MDA测定数据以表示,采用SPSS17.0统计软件包对各组数据进行t检验,结果见表1,P<0.05视为有显著性差异,P<0.01视为有非常显著性差异。
表1 氨基葡萄糖、姜黄素对急性酒精性肝损伤小鼠各项肝脏指标的影响
组别 | ALT | AST | MDA | SOD |
正常组 | 15.82±2.74 | 24.80±5.71 | 6.80±0.85 | 141.29±19.95 |
对照组 | 24.4±4.58a | 38.4±8.14a | 11.97+2.4a | 99.69±11.5a |
氨基葡萄糖组 | 18.33±3.84b | 25.4±3.95c | 8.04±1.69b | 124.65±14.87c |
姜黄素组 | 17.27±4.20b | 27.34±4.53b | 8.34±1.81b | 120.68±15.97b |
给药组1 | 18.50±3.98b | 28.86±4.73b | 10.96±3.06 | 118.48±13.76b |
给药组2 | 17.0±3.06c | 25.84±6.80b | 7.56±2.34c | 131.24±17.17c |
ALT和AST是反映肝细胞受损伤程度的指标,研究表明乙醇及其代谢产物对肝脏产生的毒性,会使血清中ALT和AST的活性升高。由表1知,小鼠灌胃两周后,与正常组比较,a:P<0.01,对照组小鼠ALT、AST水平明显升高(P<0.01),说明酒精对小鼠肝损伤显著,急性酒精性肝损伤模型造模成功;与对照组比较,b:P<0.05,c:P<0.01,各给药组能显著降低小鼠血清中的ALT、AST含量(P<0.05),表明各给药组均能够减轻小鼠因酒精引起的急性肝细胞损伤。
SOD与MDA两者反映了机体内自由基的清除与产生,SOD/MDA的比值越大,越能明显减弱自由基对机体的损害。与正常组比较,对照组小鼠SOD酶活性明显降低,MDA含量明显升高(P<0.01)。与对照组比较,药物组能显著升高小鼠肝脏的SOD含量(P<0.05)和降低小鼠肝脏的MDA含量(P<0.05),其中给药组2与对照组相比SOD与MDA含量有极其显著性差异(P<0.01),疗效优于剂量相同的氨基葡萄糖组,表明少量姜黄素对氨基葡萄糖有很好的协同增效保护小鼠急性酒精性肝损伤的作用。
3、肝组织病理观察
脱颈处死小鼠,取小鼠肝左叶下缘组织,经4%甲醛溶液固定、石蜡包埋、切片、HE染色,通过XS-212型光学显微镜观察肝组织受损情况并拍照,实验各组小鼠肝脏组织切片结果(×400)见图1~图6,其中图1对应正常组,图2对应对照组,图3对应氨基葡糖组,图4对应姜黄素组,图5对应给药组1,图6对应给药组2。
对比图1~图6可见,正常小鼠肝小叶与胞核结构清晰,细胞质丰富,没有核固缩现象,周围炎症细胞很少。对照组肝细胞小叶结构模糊,肝细胞索变窄且紊乱,有核固缩,出现死亡细胞聚集形成的坏死病灶,由此说明急性酒精性肝损伤模型造模成功。各给药组小鼠肝小叶结构清晰,肝索正常,表明肝组织受损情况减轻。其中高剂量给药组2的小鼠肝小叶清晰,肝索排列整齐,细胞质丰富,与正常肝细胞组织差异不大,从肝组织结构看,少量姜黄素确实对氨基葡萄糖有很强的协同保护急性酒精性肝损伤的作用。
综上所述,与正常组比较,对照组小鼠的ALT、AST及MDA含量均有极其显著的升高(P<0.01),SOD含量显著的降低(P<0.01),急性酒精性肝损伤造模成功;与对照组比较,各给药组均能显著降低小鼠ALT、AST、MDA水平(P<0.05),提高SOD水平(P<0.05),组织学观察各给药组小鼠的肝组织受损程度均有所减轻。结论:各给药组对急性小鼠酒精性肝损伤有干预作用,给药组对酒精性肝损伤的预防效果优于同剂量的氨基葡糖组或姜黄素组,且给药组2优于给药组1,给药组中的姜黄素与氨基葡萄糖呈现一定的协同作用。
上述组别中所用氨基葡萄糖的预处理方法为:将氨基葡萄糖盐酸盐粉碎后过100目筛网,然后将过筛得到的氨基葡萄糖盐酸盐与三乙胺按1:1摩尔比混合得到混合物,再加入该混合物重量300%的95%乙醇蒸馏水,于室温条件下搅拌5h脱盐酸,重复三次,抽滤得到固形物,对该固形物用95%乙醇洗涤3~5次至无味,得到氨基葡萄糖,将氨基葡萄糖置于真空干燥器中干燥,备用。
上述组别中所用药剂及来源为:氨基葡萄糖盐酸盐(批号:H20110706,舟山市普陀新兴医药化工有限公司);姜黄素(纯度:99.99%,宁波中药制药有限公司提供);SOD试剂盒(批号:20110628,南京建成生物工程研究所);AST试剂盒(批号:20110620,南京建成生物工程研究所);ALT试剂盒(批号:20110624,南京建成生物工程研究所);MDA试剂盒(批号:20110629,南京建成生物工程研究所);考马斯亮蓝试剂盒(批号:20110701,南京建成生物工程研究所);组织透明剂(批号:20110520,上海源叶生物科技有限公司);HE染液(批号:20110701,南京建成生物工程研究所);羧甲基纤维素钠盐(批号:F20040419,国药集团化学试剂有限公司);白酒(56度红星二锅头)。
上述组别所用检测仪器为:UV-3200PCS型紫外分光光度计(上海美谱达仪器有限公司);EL204型电子分析天平(梅勒特-托利多仪器有限公司);6-16K型高速冷冻离心机(美国Sigma公司);DF-Ⅱ型集热式磁力搅拌器(江苏金城国胜实验仪器厂);XS-212型光学显微镜(南京江南光学仪器厂);动物解剖工具一套。
将本发明药物组合物制成下述实施例1-6所列各种剂型:
实施例1:复方姜黄素氨基葡萄糖口服液
1)复方姜黄素氨基葡萄糖口服液的处方组成:
姜黄素 | 15g |
氨基葡萄糖盐酸盐 | 55g |
蔗糖 | 200g |
羧甲基纤维素钠 | 5g |
甘油 | 5g |
香精 | 适量 |
水 | 加至1000mL |
2)制备:将姜黄素粉碎后过200目筛,备用。将姜黄素、羧甲基纤维素钠、甘油充分研磨均匀后,加入纯化水200mL制成姜黄素混悬液;另取600mL水于配药罐中加热至80℃,加入氨基葡萄糖盐酸盐溶解。然后将姜黄素混悬液缓慢加入到溶解的氨基葡萄糖盐酸盐溶液中,边加边搅拌,再加入蔗糖溶解,加热至100℃完全沸腾,再开始降温,降温至30℃时,补足全量水至1000mL,进行中间产品检验,合格后,加入香精搅拌,灌封,灭菌即得。
实施例2:复方姜黄素氨基葡萄糖口服冲剂
1)氨基葡萄糖的预处理:将氨基葡萄糖盐酸盐粉碎后过100目筛网,然后将过筛得到的氨基葡萄糖盐酸盐与三乙胺按1:1摩尔比混合得到混合物,再加入该混合物重量300%的95%的乙醇水溶液,于室温条件下搅拌4h脱盐酸,重复3次,抽滤得到固形物,对该固形物用95%乙醇洗涤5次至无味,得到氨基葡萄糖,将氨基葡萄糖置于真空干燥器中干燥,备用。
2)复方姜黄素氨基葡萄糖口服冲剂的处方组成:该剂型的重量份组成为:
姜黄素 | 100g |
氨基葡萄糖 | 500g |
麦芽糊精 | 200g |
木糖醇 | 100g |
异麦芽糖醇 | 100g |
15%淀粉浆 | 适量 |
制成 | 1000g |
3)制备:按上述配比将姜黄素、氨基葡萄糖、麦芽糊精、木糖醇、异麦芽糖醇,分别粉碎后过180目筛,混匀,加入适量15%淀粉浆制软材,过20目筛制粒,于70℃下干燥,干燥颗粒过18目筛网进行整粒,质量检查合格后,分装为5g/袋。
实施例3:复方姜黄素氨基葡萄糖胶囊
1)氨基葡萄糖的预处理:将氨基葡萄糖盐酸盐粉碎后过80目筛网,然后将过筛得到的氨基葡萄糖盐酸盐与三乙胺按0.8:1摩尔比混合得到混合物,再加入该混合物重量500%的95%的乙醇水溶液,于室温条件下搅拌3h脱盐酸,重复3次,抽滤得到固形物,对该固形物用95%乙醇洗涤5次至无味,得到氨基葡萄糖,将氨基葡萄糖置于真空干燥器中干燥,备用。
2)复方姜黄素氨基葡萄糖胶囊的处方组成:该剂型的重量份组成为:
姜黄素 | 48g |
氨基葡萄糖 | 288g |
糊精 | 135g |
微晶纤维素 | 120g |
微粉硅胶 | 9g |
13%淀粉浆 | 适量 |
制成 | 1000粒 |
3)制备:按上述配比将姜黄素、氨基葡萄糖、糊精、微晶纤维素,分别粉碎后过160目筛,混匀,加入适量13%淀粉浆制软材,过20目筛制粒,于70℃下干燥,干燥颗粒过18目筛网进行整粒,再加入微粉硅胶混合均匀,质量检查合格后,灌装于1号空心硬胶囊中。
实施例4:复方姜黄素氨基葡萄糖片剂
1)氨基葡萄糖的预处理:方法如实施例2或实施例3。
2)复方姜黄素氨基葡萄糖片剂的处方组成:该剂型的重量份组成为:
姜黄素 | 80g |
氨基葡萄糖 | 200g |
麦芽糖醇 | 20g |
微晶纤维素 | 145g |
预胶化淀粉 | 50g |
硬脂酸镁 | 5g |
制成 | 1000片 |
3)制备:按上述配比将姜黄素、氨基葡萄糖、麦芽糖醇、微晶纤维素、预胶化淀粉分别粉碎后过150目筛,混匀,加入适量60%乙醇制成软材,过20目筛制粒,于60~70℃下干燥,干燥颗粒过18目筛网进行整粒,加入硬脂酸镁,混匀,压片。
实施例5:复方姜黄素氨基葡萄糖速崩片
1)氨基葡萄糖的预处理:方法如实施例2或实施例3。
2)复方姜黄素氨基葡萄糖速崩片的处方组成:该剂型的重量份组成为:
姜黄素 | 60g |
氨基葡萄糖 | 240g |
甘露醇 | 180g |
交联羧甲基淀粉钠 | 30g |
5%聚乙烯吡咯烷酮溶液 | 适量 |
微粉硅胶 | 5g |
制成 | 1000粒 |
3)制备:按上述配比将姜黄素、氨基葡萄糖、甘露醇、交联羧甲基淀粉钠分别粉碎后过160目筛,混匀,加入适量5%聚乙烯毗咯烷酮溶液作粘合剂制成软材,过20目筛制粒,于60~70℃下干燥,干燥颗粒过18目筛网进行整粒,加入微粉硅胶混匀,得速崩片。
实施例6:复方姜黄素氨基葡萄糖滴丸剂
1)氨基葡萄糖的预处理:方法如实施例2或实施例3。
2)复方姜黄素氨基葡萄糖滴丸剂的处方组成:该剂型的重量份组成为:
姜黄素 | 25g |
氨基葡萄糖 | 80g |
异麦芽糖醇 | 15g |
聚乙二醇6000 | 125g |
硬脂酸 | 5g |
制成 | 1000粒 |
3)制备:按上述配比将分别姜黄素、氨基葡萄糖、异麦芽糖醇粉碎后过200目筛,混匀。将聚乙二醇6000和硬脂酸便加热边搅拌(60~85℃)待全部熔化后,将上述混合物加入,搅拌均匀。将料液在80~85℃保温条件下迅速滴入4~8℃的甲基硅油冷凝液中,冷凝成丸。
Claims (4)
1.一种用于预防急性酒精性肝损伤的药物组合物,由主料和辅料经药物制剂技术加工制成常规剂型,其特征在于所述的主料由氨基葡萄糖和姜黄素组成,所述的氨基葡萄糖与所述的姜黄素的重量比为3~6:1。
2.根据权利要求1所述的一种用于预防急性酒精性肝损伤的药物组合物,其特征在于所述的剂型为口服液、颗粒剂、胶囊剂、片剂和滴丸剂中的任一种。
3.根据权利要求1或2所述的一种用于预防急性酒精性肝损伤的药物组合物,其特征在于所述的辅料为淀粉、糊精、蔗糖、木糖醇、异麦芽糖醇、麦芽糖醇、甘露醇、微晶纤维素、聚乙二醇-6000、预胶化淀粉、羧甲基纤维素钠、羧甲基淀粉钠、聚乙烯吡咯烷酮、交联聚维酮、微粉硅胶、硬脂酸、硬脂酸镁、水、甘油、淀粉浆、乙醇、尼泊金酯和香精中的一种或几种。
4.权利要求1所述的药物组合物的制备方法,其特征在于包括以下步骤:
1)准备氨基葡萄糖盐酸盐、姜黄素、辅料适量;
2)氨基葡萄糖的预处理:将氨基葡萄糖盐酸盐粉碎后过80~300目筛网,然后将过筛得到的氨基葡萄糖盐酸盐与三乙胺按0.6~1.2:1摩尔比混合得到混合物,再加入该混合物重量100~500%的95%的乙醇水溶液,于室温条件下搅拌3~8h脱盐酸,重复三次,抽滤得到固形物,对该固形物用95%乙醇洗涤3~5次至无味,得到氨基葡萄糖,将氨基葡萄糖置于真空干燥器中干燥,备用;
3)将得到的氨基葡萄糖以及预先准备的姜黄素和辅料按药物制剂技术加工制成所需剂型,该剂型的药物组合物的主料由氨基葡萄糖和姜黄素组成,氨基葡萄糖与姜黄素的重量比为3~6:1。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410491590.2A CN104288164B (zh) | 2014-09-24 | 2014-09-24 | 一种用于预防急性酒精性肝损伤的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410491590.2A CN104288164B (zh) | 2014-09-24 | 2014-09-24 | 一种用于预防急性酒精性肝损伤的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104288164A CN104288164A (zh) | 2015-01-21 |
CN104288164B true CN104288164B (zh) | 2017-01-11 |
Family
ID=52308279
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410491590.2A Expired - Fee Related CN104288164B (zh) | 2014-09-24 | 2014-09-24 | 一种用于预防急性酒精性肝损伤的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104288164B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI634902B (zh) | 2017-10-28 | 2018-09-11 | 醫療財團法人徐元智先生醫藥基金會亞東紀念醫院 | Use of glucosamine peptide compounds for the treatment of abnormal liver metabolism |
CN112535715B (zh) * | 2019-09-20 | 2022-04-15 | 江阴持一堂医药科技有限公司 | 一种治疗酒精性肝损伤的中药组合物及中药制剂和应用 |
CN112535716B (zh) * | 2019-09-20 | 2022-04-15 | 江阴持一堂医药科技有限公司 | 一种用于治疗酒精性肝损伤的颗粒剂及其制备方法和应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1049006C (zh) * | 1996-12-27 | 2000-02-02 | 中国人民解放军第三军医大学 | 以n-乙酰-d-氨基葡萄糖作为添加剂的保健酒 |
US20090082738A1 (en) * | 2007-09-24 | 2009-03-26 | Vad Vijay B | Natural Anti-Inflammatory Agents for Reducing Pain |
CN101239168A (zh) * | 2008-01-11 | 2008-08-13 | 王玉亮 | 一种具有镇痛抗炎作用的组合物 |
CN101889679B (zh) * | 2009-05-20 | 2012-09-26 | 凌沛学 | 一种具有解酒保肝作用的组合物及其在食品、保健食品中的应用 |
CN102698254B (zh) * | 2012-06-05 | 2013-08-14 | 哈尔滨珍宝制药有限公司 | 一种增加骨密度的组合物,含其制剂及其制备方法 |
CN103709208B (zh) * | 2014-01-16 | 2016-08-17 | 江苏九寿堂生物制品有限公司 | 一种氨基葡萄糖单体的制备方法 |
-
2014
- 2014-09-24 CN CN201410491590.2A patent/CN104288164B/zh not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
壳寡糖、氨基葡萄糖对酒精性肝损伤小鼠的保护作用;刘亮亮 等;《中国海洋大学学报》;20100731;第40卷(第7期);073-076 * |
Also Published As
Publication number | Publication date |
---|---|
CN104288164A (zh) | 2015-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102552549B (zh) | 一种改善视疲劳的组合物及其制备方法和应用 | |
CN104288164B (zh) | 一种用于预防急性酒精性肝损伤的药物组合物 | |
CN101199668B (zh) | 一种治疗酒精性脂肪肝的中药制剂及其制备方法 | |
CN1278737C (zh) | 一种具有生物活性的复方药物制剂 | |
TWI763970B (zh) | 角豆樹果組合物及其製備方法與應用 | |
CN105983016B (zh) | 一种含有水飞蓟宾的药物组合 | |
CN107551001B (zh) | 一种用于防治酒精性肝损伤的中药复合物及其制法 | |
CN1425447A (zh) | 一种治疗小儿食积咳嗽的中药组合物及其制备方法 | |
CN103566282B (zh) | 一种抗肿瘤作用中药组合物及制备方法 | |
CN115444922B (zh) | 一种抗疲劳药食同源组合物及其应用 | |
CN104926958B (zh) | 从泽兰中提取泽兰多糖的方法及其应用 | |
CN1759738A (zh) | 一种具有抗辐射功能的蜂产品保健品 | |
CN102228666B (zh) | 来自松花粉与姜黄的组合物及其制备方法和在制备治疗炎症性肠病的药物中的应用 | |
CN109925445A (zh) | 金线莲提取物在制备预防和/或治疗d-氨基半乳糖致小鼠急性肝损伤药物中的应用 | |
CN103877323B (zh) | 一种用于防治非酒精性脂肪肝的药物组合物 | |
CN105327115B (zh) | 一种防治ⅱ型糖尿病桑黄通泻配方及制备工艺 | |
CN104547588B (zh) | 一种胃康灵滴丸的制备方法 | |
CN103006633A (zh) | 羟基红花黄色素a在制备抗阿尔茨海默病药物中的应用 | |
CN104367612B (zh) | 一种狗蚁草提取物的应用 | |
CN103127319A (zh) | 鸢尾科红葱属植物红葱及其提取物的降脂作用 | |
CN105920053A (zh) | 桑黄精细粉制备方法 | |
Hu | Nutraceutical innovation and health claims in China | |
CN103623109A (zh) | 一种治疗缺血性脑血管病的中药组合物及其制备方法 | |
CN105285977A (zh) | 一种具有抗衰老、提高免疫力功效的保健品 | |
CN109876088A (zh) | 一种通过调节肠道菌群平衡发挥降糖作用的天然降糖制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170111 Termination date: 20170924 |
|
CF01 | Termination of patent right due to non-payment of annual fee |